Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Pulmatrix, Inc.    PULM

PULMATRIX, INC.

(PULM)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

PULMATRIX, INC. : Change in Directors or Principal Officers (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
11/18/2019 | 10:19am EST

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officer.

On November 13, 2019, Pulmatrix, Inc. (the "Company") appointed Michelle Siegert, Vice President, Finance of the Company, as the principal financial and accounting officer of the Company, effective as of November 22, 2019.

Ms. Siegert, 59, was promoted to Vice President, Finance of the Company in November, 2019. Ms. Siegert joined the Company in 2010 and has held various roles of increasing responsibility in finance and accounting serving most recently as Vice President, Corporate Controller. Prior positions held at the Company include: Senior Director, Finance and Accounting, Director, Finance and Accounting, and Controller. Ms. Siegert holds a B.A. in Management from Simmons University with a concentration in Accounting.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PULMATRIX, INC.
01/30PULMATRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/30PULMATRIX : Receives Fast Track Designation for Pulmazole for the Treatment of A..
PR
01/16PULMATRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/16PULMATRIX : Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR
01/13PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
01/06PULMATRIX : Announces Research Collaboration with Nocion Therapeutics to Explore..
PR
01/02PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
AQ
01/02PULMATRIX : Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Init..
PR
2019PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2019PULMATRIX, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Financials (USD)
Sales 2019 6,23 M
EBIT 2019 -14,7 M
Net income 2019 -15,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -1,56x
P/E ratio 2020 -1,40x
Capi. / Sales2019 4,46x
Capi. / Sales2020 infx
Capitalization 27,8 M
Chart PULMATRIX, INC.
Duration : Period :
Pulmatrix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PULMATRIX, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 10,00  $
Last Close Price 1,39  $
Spread / Highest target 619%
Spread / Average Target 619%
Spread / Lowest Target 619%
EPS Revisions
Managers
NameTitle
Teofilo Raad President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
Michelle Siegert Chief Financial & Accounting Officer
Steven H. Gillis Independent Director
Michael John Higgins Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX, INC.61.63%28
GILEAD SCIENCES14.96%94 394
VERTEX PHARMACEUTICALS1.99%60 161
REGENERON PHARMACEUTICALS21.96%49 848
WUXI APPTEC CO., LTD.20.01%25 883
GENMAB A/S13.09%15 615